Scientists Are Testing a Gene Therapy That Could Reverse Cellular Aging in Humans

From billionaire-backed biotech to promising animal studies, this early trial will test whether partial reprogramming can ...
Nature

Magnetic muon measurements and gene-therapy advances win US$3 million Breakthrough prizes

Three life-science prizes were awarded for advances in gene therapies. Opthalmologists Jean Bennett and Albert Maguire, and ...
Fierce Biotech

Eying 3 approvals in 2 years, Ocugen’s CEO wants to bring gene therapy to the masses

To Ocugen CEO Shankar Musunuri, Ph.D., most gene therapy biotechs today lack vision. | Many gene therapy outfits focus on ...

Gene Therapy Market Report 2026-2034 - CRISPR and AAV Technologies Propel Gene Therapy Advancements; Global Market Growing at 12.27% CAGR

The global gene therapy market size is projected to expand significantly, with an estimated value of USD 19.3 billion by 2034 ...
The Scientist

Gene Therapy Pioneers Win 2026 Breakthrough Prize

The Breakthrough Prize Foundation awarded researchers involved in developing gene therapies for blindness and sickle cell ...
Healio

VIDEO: Gene therapy emerging option for primary immunodeficiency treatment

The treatment for primary immunodeficient diseases is varied. As mentioned before, the most common type of primary immunodeficient disease are antibody deficiencies. Either patients don't make enough ...
Fierce Biotech

Johnson & Johnson hands back failed eye disease gene therapy to MeiraGTx

After its bet on a rare eye disease gene therapy ended in a phase 3 fail last year, Johnson & Johnson is now returning the ...

For regrowing human limbs, this salamander gene could hold the key

Investigating a common gene in three very different species—salamanders, mice and zebrafish—scientists have discovered the ...
Managed Healthcare Executive

Gene therapy may be a once-in-lifetime treatment. That gives some patients and providers pause and a willingness to ‘wait it out’ until a better therapy comes along …

Pfizer announced in February 2025 that it was taking Beqvez (fidanacogene elaparvovec), its gene therapy for hemophilia B, ...
Managed Healthcare Executive

Gene therapy brims with promise. The reality has been less rosy for some therapies | AMCP Annual 2026

Pfizer and BioMarin have pulled their hemophilia gene therapies, citing low demand. To prepare for his presentation at the ...

Medera Receives FDA Fast Track Designation for Gene Therapy Targeting Duchenne Muscular Dystrophy-Associated Cardiomyopathy

Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company developing next-generation cardiovascular therapeutics, ...

DNA Patent Eligibility Under Spotlight in Sarepta’s En Banc Bid

Sarepta Therapeutics Inc.'s bid for the full Federal Circuit’s review of a revived gene-therapy patent dispute with RegenxBio ...